by Tom Ruginis | Dec 28, 2017 | Start-ups |
When we last checked in a year ago, Perlara had just achieved three critical milestones: a product (PerlQuest), a validating Pharma deal, and first revenue – a small check, but revenue nonetheless. Over the course of 2017, we transitioned from startup with a...
by Ethan Perlstein | Nov 4, 2017 | Start-ups, Uncategorized |
This week we announced a $7.4M equity financing. Endpoints News and STAT News covered the announcement and the Twitter angle. Here’s the backstory from the CEO’s vantage point. From the outside, this round appears to be our Series A. But it’s technically our...
by Ethan Perlstein | Jul 31, 2017 | Start-ups |
Perlara midsummer 2017 updates—We took a temporary hiatus from blogging starting in March right after my Rare Disease Day post. The reason: fundraising. Raising money is personally all-consuming for the CEO, as I’ll attest in an upcoming post. It’s also a...
by Tom Ruginis | Dec 13, 2016 | Start-ups |
As 2016 draws to a close, we look back on two and half years of Perlara spending. Let’s begin with burn rate. This figure shows our monthly burn since first cash inflows in April 2014: In 2014, we completed model validation and assay development for our lead discovery...
by Ethan Perlstein | Oct 8, 2016 | Start-ups |
Last month at the 5th annual Global Genes Patient Summit, we announced our rebrand from Perlstein Lab PBC to Perlara PBC. Together with our partners at Valley Design Group, we created a new logo/mark that embodies the excitement and hope of scientific discovery. To go...
by Ethan Perlstein | Apr 30, 2016 | Start-ups |
11-year old startup accelerator Y Combinator – “YC” for those in the know – has reached national (and international) acclaim for incubating today’s premier tech unicorns back when they were hatchlings. Companies with instant name recognition, like Airbnb (W09)...
